After moving 4.4% during today's evening session, BeiGene is now trading at a price of $202.8 per share. On average, analysts give it a target price of $296.03.
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide.
BeiGene Investors Should Consider This:
-
BeiGene has moved 15.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of 0.11. A number between 0 and 1 could mean that the market is undervaluing BeiGene's estimated growth potential
-
Its Price to Book (P/B) ratio is 5.59
Understanding BeiGene's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-27 | 1,415,921 | -2,919,111 | -126 | -3.28 |
| 2022-02-28 | 1,176,283 | -2,450,112 | -122 | 77.28 |
| 2021-02-25 | 308,874 | -1,895,899 | -537 | -139.73 |
| 2020-03-02 | 428,212 | -1,316,913 | -224 | 37.08 |
| 2019-02-28 | 198,220 | -875,284 | -356 | -768.29 |
| 2018-02-28 | 238,387 | -331,870 | -41 |
Averaging out to -234.3% over the last 6 years, BeiGene's operating margins also have a high coefficient of variability, which stands at 78.3%. The firm's margins are declining at a -20.6% compounded yearly rate.
